Associate Director, QSP Modeling
Moderna, Inc.
Oleg Milberg, Ph.D., is currently a Director of Quantitative Pharmacology at Regeneron. He previously worked as an Associate Director at Moderna covering preclinical, clinical, and QSP projects across the entire spectrum of the mRNA platform, including therapeutics, such as Oncology, Autoimmune, and Rare Diseases, and Vaccines. Along the same lines, his prior experience and research focused on model-driven drug development at both the preclinical and clinical levels in places such as Janssen Pharmaceuticals, Johns Hopkins Biomedical Engineering - where he published a QSP model that predicts clinical outcomes of monotherapy, combination, and sequential therapy following PD-1, PD-L1 and CTLA-4 checkpoint IO therapies - and through his research at the NIH and internships at Merck and Schering-Plough in Process Development and Manufacturing. Overall, Oleg has a great interest in the science and potential of novel modalities to help patients and is a big proponent of using model-informed drug development techniques to make those therapies a reality, as they move from bench to bedside.
Disclosure information not submitted.
Wednesday, October 19, 2022
9:30 AM – 10:00 AM ET